おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
somatropin
メーカー／製品名
EDQM
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
−20°C
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Somatropin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
Choose from one of the most recent versions:
試験成績書（COA）
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact カスタマーサポート
Editor's commentary: sex hormone priming.
Zvi Laron
Pediatric endocrinology reviews : PER, 11(3), 288-288 (2014-04-11)
Z Gucev et al.
Pediatric endocrinology reviews : PER, 11(3), 337-338 (2014-04-11)
The Second meeting on Rare Diseases in South Eastern Europe (SEE) was held in Skope, Macedonia on November 15-16, 2013. Objective and main data: Rare diseases (RD) are a major problem in developed and especially in countries without affluence. 6-8%
Marianne Klose et al.
The Journal of clinical endocrinology and metabolism, 99(1), 101-110 (2013-11-19)
Recent international guidelines suggest pituitary screening in patients with moderate and severe traumatic brain injury (TBI). Predominantly isolated GH deficiency (GHD) was reported in the literature, raising the question of potential methodological bias. Our objective was to assess the prevalence
Long-acting growth hormone.
Charlotte Höybye et al.
Paediatric drugs, 15(6), 427-429 (2013-11-20)
Vita Birzniece et al.
European journal of endocrinology, 170(3), 375-383 (2013-12-19)
GH action is attenuated by estrogens and selective estrogen receptor modulators (SERMs) administered orally. During GH therapy in hypopituitary women, co-treatment with raloxifene, a SERM, induced a smaller gain in lean body mass (LBM) compared with estrogen, despite an equal
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）